Welcome!

News Feed Item

Assurex Health Names Burns Executive Chairman, Promotes Drosos to Chief Executive Officer

Assurex Health, the leading personalized medicine company helping physicians select the right medication for patients with mental health disorders and chronic pain, named James S. Burns Executive Chairman and Virginia (Gina) C. Drosos as President and Chief Executive Officer, effective July 1, 2014.

Assurex Health Leadership Team (from left to right): James Burns, Executive Chairman; Virginia (Gina ...

Assurex Health Leadership Team (from left to right): James Burns, Executive Chairman; Virginia (Gina) Drosos, President and Chief Executive Officer; and Donald Wright, Chief Operating Officer. (Photo: Business Wire)

Burns, who has served as CEO since 2009, will chair the Board of Directors, as well as focusing on long-term development of Assurex Health’s proprietary technology platform and overseeing the company’s Scientific Advisory Board. Drosos, who joined the company in August 2013, adds the CEO role to her responsibilities as President and leader of the commercial organization and fast growing program to drive broad awareness and adoption of GeneSight.

Company Chief Operating Officer, Donald R. Wright, who has led Assurex operations since 2008, will continue to lead major Assurex Health initiatives related to informatics innovation, product development, laboratory operations, reimbursement, human resources and government affairs.

“Assurex Health has been built on industry-leading genetic technology, informatics, intellectual property, and clinical data,” said Burns. “We address a very large market for our GeneSight products with a demonstrated clinical and economic benefit. Our goal now is to scale the company commercially and make GeneSight technology broadly available to clinicians and their patients. Gina has the proven leadership qualities and ability to scale the company and lead a substantial expansion of our patient and clinician customer base. Gina, Don, and I will continue working closely together to help make GeneSight-enabled mental wellness a reality.”

Fast Growth Signals Increasing Acceptance of Flagship GeneSight Test

The new management roles allow Assurex Health to enhance its focus on leading-edge science, clinical data and driving awareness and adoption as it continues its rapid growth, helping thousands of clinicians select the right medications for nearly 100,000 patients with neuropsychiatric disorders. In the past year, Assurex Health has almost doubled its workforce to more than 200 employees, and doubled the number of patients it tests each month.

Assurex Health’s GeneSight technology helps guide clinicians making medication decisions for patients with neuropsychiatric disorders such as depression, PTSD, ADHD, bipolar disorder, or chronic pain. Compared with the current standard of care, patients whose treatment was guided by GeneSight had double the odds of remission and response to medication, and experienced 70 percent greater improvement in depressive symptoms.

“Under Jim’s leadership, we are seeing tremendous growth and success, and I am honored to succeed him as CEO,” Drosos said. “My vision for Assurex Health is to make GeneSight a standard of care. We remain dedicated to helping clinicians better their treatment of patients with mental health disorders, changing how neuropsychiatric medicines are prescribed, and helping speed patients on the road to recovery.”

“With Gina in her new role, I am excited to see where we can take this company,” said Wright. “We have come a long way in developing informatics-based products that are clinically relevant and easy to use. Now, we’re helping more clinicians and patients across the country than ever before realize there is a better, more effective way to make and manage medication decisions.”

Enhanced Coverage, Strong Support

Assurex Health continues to rapidly increase the number of health plans that reimburse the cost of GeneSight testing. This includes government payers, as well as growing relationships with commercial payer organizations. Last month, Assurex Health announced that it had become an in-network provider with The Alliance, a not-for-profit cooperative serving employers who self-fund their health benefits in Wisconsin, Illinois and Iowa. Today, Assurex Health announced that it has joined the SIHO Insurance Services Provider Network, an innovative cooperative of local physicians, hospitals and employers in the Midwest.

About GeneSight

GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric medications. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, manufacturers’ FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology.

Assurex Health has four laboratory developed tests powered by GeneSight technology. The GeneSight Psychotropic test analyzes how a patient’s genes may affect his/her metabolism and response to FDA-approved medicines commonly prescribed to treat depression, anxiety, bipolar disease, schizophrenia or other behavioral health conditions. GeneSight Analgesic gives physicians a powerful genetic-based tool to help evaluate medication responses for patients with acute or chronic pain across four drug classes: opioids, NSAIDs, muscle relaxants and opioid dependency medications. GeneSight ADHD provides information about patient response to ADHD medications, including stimulant and non-stimulant medications. GeneSight MTHFR helps determine if additional folic acid supplementation is necessary. More than 8,000 healthcare practitioners have used GeneSight to guide treatment decisions for over 90,000 patients.

About Assurex Health

Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients with neuropsychiatric and other medical conditions. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric conditions. Assurex Health has licensed patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center.

Assurex recently disclosed a $32 million financing round from GE Capital, Silicon Valley Bank and additional investments by Sequoia Capital, Claremont Creek Ventures, CincyTech, Allos Ventures, and others. The company also launched its first product-specific website for GeneSight earlier this month. Learn more at www.assurexhealth.com and www.genesight.com. Assurex Health is a DBA of AssureRx Health, Inc.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Real IoT production deployments running at scale are collecting sensor data from hundreds / thousands / millions of devices. The goal is to take business-critical actions on the real-time data and find insights from stored datasets. In his session at @ThingsExpo, John Walicki, Watson IoT Developer Advocate at IBM Cloud, will provide a fast-paced developer journey that follows the IoT sensor data from generation, to edge gateway, to edge analytics, to encryption, to the IBM Bluemix cloud, to Wa...
With the rise of DevOps, containers are at the brink of becoming a pervasive technology in Enterprise IT to accelerate application delivery for the business. When it comes to adopting containers in the enterprise, security is the highest adoption barrier. Is your organization ready to address the security risks with containers for your DevOps environment? In his session at @DevOpsSummit at 21st Cloud Expo, Chris Van Tuin, Chief Technologist, NA West at Red Hat, will discuss: The top security r...
SYS-CON Events announced today that Fusic will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Fusic Co. provides mocks as virtual IoT devices. You can customize mocks, and get any amount of data at any time in your test. For more information, visit https://fusic.co.jp/english/.
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 21st Cloud Expo, Lennart Frantzell, a Developer Advocate with IBM, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing devel...
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp em...
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...